TriLink Biotechnologies

Executive Summary

TriLink Biotechnologies is a specialized provider of modified nucleic acid synthesis and manufacturing services, serving research, diagnostic, and therapeutic applications. As a key enabler in the RNA field, the company offers CleanCap® mRNA capping reagents, custom oligos, and GMP manufacturing for clinical and commercial supply. Founded in 1996 and based in San Diego, TriLink has established itself as a critical supplier and CDMO for the rapidly growing RNA sector. With the expansion of mRNA vaccines and therapeutics, TriLink is well-positioned to benefit from increased demand for high-quality reagents and contract manufacturing. The company's pre-clinical stage reflects its focus on enabling technologies rather than developing its own therapeutics, making it a low-risk play on the RNA ecosystem. Strong customer relationships and a track record of innovation support its competitive advantage.

Upcoming Catalysts (preview)

• Q3 2026Expansion of GMP manufacturing capacity for mRNA capping reagents80% success
• Q4 2026Strategic partnership or supply agreement with a major mRNA therapeutics company60% success
• Q2 2026Launch of new modified nucleotide products for emerging RNA applications70% success